Sorriso Pharmaceuticals, Inc.
Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis. The company focuses on developing potent, orally deliverable antibodies designed to maintain activity throughout the human intestine, with a lead candidate, SOR102, targeting inflammatory bowel disease (IBD).
Industries
Nr. of Employees
small (1-50)
Sorriso Pharmaceuticals, Inc.
Patents
Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R)
US-12247079-B2
View DetailsPolypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases
US-12098197-B2
View DetailsVHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases
US-11667719-B2
View Details
Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R)
US-12247079-B2
View DetailsPolypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases
US-12098197-B2
View DetailsVHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases
US-11667719-B2
View DetailsProducts
Oral gut-restricted anti-TNF program
Development of an orally delivered, gut-restricted anti-TNF therapeutic intended to concentrate activity in the intestine for inflammatory conditions such as ICI-mediated colitis.
Oral bispecific anti-TNF/anti-IL-23 program (early clinical)
Development and clinical evaluation of an orally delivered bispecific antibody that targets TNFα and IL-23 locally within inflamed gastrointestinal tissue; advanced into Phase 1b clinical studies with reported data presentations.
Anti-IL-7Rα (IL-7/TSLP) program for oral or inhaled delivery
Program developing an anti-IL-7Rα domain antibody intended to block IL-7 and TSLP signaling; formulated for local delivery either orally (GI) or via inhalation (pulmonary indications such as asthma).
Oral gut-restricted anti-TNF program
Development of an orally delivered, gut-restricted anti-TNF therapeutic intended to concentrate activity in the intestine for inflammatory conditions such as ICI-mediated colitis.
Oral bispecific anti-TNF/anti-IL-23 program (early clinical)
Development and clinical evaluation of an orally delivered bispecific antibody that targets TNFα and IL-23 locally within inflamed gastrointestinal tissue; advanced into Phase 1b clinical studies with reported data presentations.
Anti-IL-7Rα (IL-7/TSLP) program for oral or inhaled delivery
Program developing an anti-IL-7Rα domain antibody intended to block IL-7 and TSLP signaling; formulated for local delivery either orally (GI) or via inhalation (pulmonary indications such as asthma).
Expertise Areas
- Oral biologic therapeutics
- Single-domain antibody engineering
- Bispecific/multispecific antibody design
- Local tissue-targeted delivery
Key Technologies
- Single-domain antibody (domain antibody) constructs
- Bispecific/multivalent antibody formats
- Oral and inhaled biologic delivery platforms
- Yeast expression systems for protein production